Product
CMAB007
2 clinical trials
2 indications
Indication
Chronic Spontaneous UrticariaIndication
Healthy Control ParticipantsClinical trial
A Multicenter, Randomized, Double-Blind, Positive Parallel Controlled Phase III Clinical Trial to Compare Omalizumab α(CMAB007) and Xolair® in Patients With Chronic Spontaneous UrticariaStatus: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
Phase I Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of CMAB007 and Xolair in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male SubjectsStatus: Completed, Estimated PCD: 2022-06-27